Coat of proteins makes viruses more infectious and links them to Alzheimer's disease
New research from Stockholm University and Karolinska Institutet shows that viruses interact with proteins in the biological fluids of their host which results in a layer of proteins on the viral surface. This coat of proteins makes the virus more infectious and facilitates the formation of plaques characteristic of neurodegenerative diseases such as Alzheimer's disease.

Proteins in the fluid surrounding the target cell bind to a virus and can make it more infectious. The virus can also accelerate the formation of threadlike amyloid fibrils that play a part in Alzheimer's disease.
E. Wikander/Azote/Stockholm University
Are viruses dead or alive? Well... both. Viruses can only reproduce inside living cells and exploit the cellular machinery of their host to their benefit. However, before entering a host cell, viruses are just nanometer-sized particles, very similar to artificial nanoparticles used in medical applications for diagnosis and therapy. Scientists from Stockholm University and Karolinska Institutet have found that viruses and nanoparticles share another important property; they both become covered by a layer of proteins when they encounter the biological fluids of their host before they find their target cell. This layer of proteins on the surface influence their biological activity significantly.
"Imagine a tennis ball falling into a bowl of milk and cereals. The ball is immediately covered by the sticky particles in the mix and they remain on the ball when you take it out of the bowl. The same thing happens when a virus gets in contact with blood or lung fluids that contain thousands of proteins. Many of these proteins immediately stick to the viral surface forming a so-called protein corona", Kariem Ezzat of Stockholm University and Karolinska Institutet explains.
Kariem Ezzat and his colleagues studied the protein corona of respiratory syncytial virus (RSV) in different biological fluids. RSV is the most common cause of acute lower respiratory tract infections in young children worldwide, leading up to 34 million cases and 196,000 fatalities each year. "The protein corona signature of RSV in the blood is very different from that in lung fluids. It is also different between humans and other species such as rhesus macaque monkeys, which also can be infected with RSV", Kariem Ezzat says. "The virus remains unchanged on the genetic level. It just acquires different identities by accumulating different protein coronae on its surface depending on its environment. This makes it possible for the virus to use extracellular host factors for its benefit, and we've shown that many of these different coronae make RSV more infectious."
The researchers from Stockholm University and Karolinska Institutet have also found that viruses such as RSV and herpes simplex virus type 1 (HSV-1) can bind a special class of proteins called amyloid proteins. Amyloid proteins aggregate into plaques that play a part in Alzheimer's disease where they lead to neuronal cell death. The mechanism behind the connection between viruses and amyloid plaques has been hard to find till now, but Kariem Ezzat and his colleagues found that HSV-1 is able to accelerate the transformation of soluble amyloid proteins into thread-like structures that constitute the amyloid plaques. In animal models of Alzheimer's disease, they saw that mice developed the disease within 48 hours of infection in the brain. In absence of an HSV-1 infection the process normally takes several months.
"The novel mechanisms described in our paper can have an impact not only on understanding new factors determining how infectious a virus is, but also on devising new ways to design vaccines. In addition, describing a physical mechanism that links viral and amyloid causes of disease adds weight to the increasing research interest in the role of microbes in neurodegenerative disorders such as Alzheimer's disease and opens up new avenues for treatments.", Kariem Ezzat of Stockholm University and Karolinska Institutet says.
Original publication
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Automated, cost-effective production of mRNA vaccines as well as cell and gene therapeutics - “The system will enable automated, component-based, flexible and validatable production”
Montezuma's_Revenge_(illness)
Fermentation research groups start the worldwide research challenge “BlueCompetition”

Breakthrough for an Alternative to Crude Oil & Palm Oil - OLIPI Receives €1.8 Million Seed Funding for Further Development of CO2-Neutral Climate Oil

Why words become harder to remember as we get older
Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon

New weapon against hepatitis D - Paving the way for drug therapy of the particularly aggressive liver disease
Photocure announces results from phase II study in acne with Visonac

Researchers develop “time machine for biodiversity” - AI shows species decline in a swimming lake
